NCT00543504 is a Phase 1 clinical trial of Bevacizumab in Advanced Cancer, sponsored by M.D. Anderson Cancer Center.

Who is sponsoring NCT00543504?

NCT00543504 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00543504?

Interventions in NCT00543504: Bevacizumab, Sorafenib, Erlotinib, Trastuzumab, Lapatinib, Sunitinib, Cetuximab.

What condition does NCT00543504 study?

NCT00543504 studies Advanced Cancer.

Is NCT00543504 still recruiting?

NCT00543504 is currently completed. Last updated 30 June 2020.

Last reviewed 2020-06-30 · How we verify

NCT00543504

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab in Multiple Phase I Combinations

Completed Phase 1 Last updated 30 June 2020

What this trial tests

Phase 1 trial testing Bevacizumab in Advanced Cancer in 343 participants. Completed in 29 April 2020.

Timeline

10 October 2007

Primary endpoint
29 April 2020

29 April 2020

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	343
Start date	10 October 2007
Primary completion	29 April 2020
Estimated completion	29 April 2020
Sites	1 location across United States

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Sorafenib
Erlotinib
Trastuzumab (trastuzumab) — full drug profile →
Lapatinib (LAPATINIB) — full drug profile →
Sunitinib (sunitinib) — full drug profile →
Cetuximab (cetuximab) — full drug profile →

Conditions studied

Advanced Cancer — all drugs for Advanced Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Eligibility, any sex, with Advanced Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to find the highest tolerable dose of Avastin™ that can be given in combination with 4 other study drug/drug combinations. It will be given with sunitinib, with sorafenib, with a combination of erlotinib and cetuximab, and with a combination of trastuzumab and lapatinib. The safety and effectiveness of these drug combinations will also be studied.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer.
Falchook GS, Moulder SL, Wheler JJ, Jiang Y, et al · · 2013 · cited 27× · PMID 24158411 · DOI 10.1093/annonc/mdt395
Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.
Falchook GS, Janku F, Tsao AS, Bastida CC, et al · · 2013 · cited 24× · PMID 23328556 · DOI 10.1097/jto.0b013e31827ce38e
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Wheler J, Falchook G, Tsimberidou AM, Hong D, et al · · 2013 · cited 15× · PMID 23800712 · DOI 10.18632/oncotarget.1028
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
Subbiah V, Dumbrava EI, Jiang Y, Thein KZ, et al · · 2020 · cited 12× · PMID 32337094 · DOI 10.1186/s40164-020-00159-1
Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases.
Yang X, Ren H, Xu Y, Peng X, et al · · 2023 · cited 4× · PMID 36642742 · DOI 10.1186/s40001-022-00894-7

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Advanced Cancer

Currently open trials in the same condition.

NCT07393529 — A Pilot Randomized Controlled Trial of a Social Network Intervention · NA · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07246954 — A Chaplain-clinician Led Spiritual Care (PEACE) Intervention on Spiritual/Religious Beliefs Related to Medical Care in P · NA · recruiting
NCT06346197 — Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas · Phase 3 · recruiting
NCT07147023 — Better Real-time Information on Documentation of Goals of Care for Engagement in Serious Illness Communication · NA · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00543504 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 30 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00543504.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing